Zai Lab Ltd (ZLAB) — SEC Filings
Zai Lab Ltd (ZLAB) — 30 SEC filings. Latest: 10-Q (May 7, 2026). Includes 11 8-K, 7 10-Q, 4 SC 13G/A.
Overview
Zai Lab Ltd (ZLAB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Zai Lab Ltd. reported total revenues of $116.095 million for the three months ended September 30, 2025, an increase from $102.265 million in the same period of 2024. Product revenue, net, grew to $115.361 million from $101.847 million year-over-year. Despite revenue growth, the company's net loss fo
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Zai Lab Ltd is neutral.
Filing Type Overview
Zai Lab Ltd (ZLAB) has filed 1 4, 1 144, 7 10-Q, 11 8-K, 2 DEF 14A, 3 SC 13G, 4 SC 13G/A, 1 10-K with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of ZLAB's 22 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $116.095M |
| Net Income | -$35.963M |
| EPS | -$0.03 |
| Debt-to-Equity | 0.52 |
| Cash Position | $717.155M |
| Operating Margin | -30.9% |
| Total Assets | $1,158.940M |
| Total Debt | $203.026M |
Key Executives
- Dr. William Lu
- Yong (Ben) Kang
- Dr. Ge Li
- Ms. Jian (Jane) Huang
- Mr. Jonathan M. Wang
- December 29, 2023
- Abigail P. Johnson
- Massachusetts
- February 8, 2024
Industry Context
Zai Lab operates in the highly competitive biopharmaceutical industry, focusing on developing and commercializing innovative medicines for oncology, autoimmune diseases, and infectious diseases. The sector is characterized by significant R&D investment, lengthy drug development cycles, and stringent regulatory oversight from bodies like the FDA and NMPA. Key trends include advancements in precision medicine, biologics, and the increasing importance of strategic partnerships for market access and pipeline expansion.
Top Tags
financial-obligation (4) · 10-Q (4) · institutional-ownership (4) · Pharmaceuticals (3) · material-agreement (3) · Zai Lab (3) · Biotechnology (2) · R&D Spending (2) · Net Loss (2) · SEC Filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues | $116.095M | Increased from $102.265M in Q3 2024, showing 13.5% growth. |
| Net Loss | $35.963M | Improved from $41.671M in Q3 2024, a 13.7% reduction in loss. |
| R&D Expenses | $47.928M | Decreased by 27.4% from $65.982M in Q3 2024, indicating cost control. |
| Cash & Cash Equivalents | $717.155M | Increased significantly from $449.667M at year-end 2024, bolstering liquidity. |
| Accumulated Deficit | $2,578.211M | Widened from $2,453.083M, reflecting ongoing operational losses. |
| Proceeds from Short-term Debt | $185.564M | Contributed to cash flow, but also increased short-term debt to $203.026M. |
| Maturity of Short-term Investment | $330.000M | Major contributor to increased cash, showing asset liquidity. |
| Loss per Share | $0.03 | Improved from $0.04 in Q3 2024, indicating better per-share performance. |
| Q2 2025 Net Loss | $105.3M | Increased from $90.1M in Q2 2024, indicating widening losses. |
| Six-Month Net Loss | $201.2M | Widened from $175.5M in the prior year, showing continued unprofitability. |
| Total Liabilities | $500.5M | Increased from $480.2M at year-end 2024, adding to financial obligations. |
| Common Shares Outstanding | 96.2M | Stable as of July 31, 2025, indicating no recent significant dilution from new share issuance. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
| Previous Fiscal Year End | 2024-12-31 | Provides a comparison point to the prior year's financial standing. |
| Comparative Period | 2024-01-01 to 2024-03-31 | Shows financial data for the same period in the previous year for comparison. |
Forward-Looking Statements
- {"claim":"Capital World Investors will maintain a significant stake in Zai Lab Ltd. for the foreseeable future.","entity":"Capital World Investors","targetDate":"2025-12-31","confidence":"high"}
- {"claim":"Zai Lab Ltd. will continue to be a focus for institutional investors due to its pharmaceutical preparations classification.","entity":"Zai Lab Ltd.","targetDate":"2024-12-31","confidence":"medium"}
- {"claim":"FMR LLC will continue to be a significant institutional holder of Zai Lab Ltd shares.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"Zai Lab Ltd. will likely see continued institutional interest due to Wellington Management's significant stake.","entity":"Zai Lab Ltd.","targetDate":"2025-02-08","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Zai Lab Ltd (ZLAB)?
Zai Lab Ltd has 30 recent SEC filings from Feb 2024 to May 2026, including 11 8-K, 7 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ZLAB filings?
Across 30 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Zai Lab Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Zai Lab Ltd (ZLAB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Zai Lab Ltd?
Key financial highlights from Zai Lab Ltd's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ZLAB?
The investment thesis for ZLAB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Zai Lab Ltd?
Key executives identified across Zai Lab Ltd's filings include Dr. William Lu, Yong (Ben) Kang, Dr. Ge Li, Ms. Jian (Jane) Huang, Mr. Jonathan M. Wang and 4 others.
What are the main risk factors for Zai Lab Ltd stock?
Of ZLAB's 22 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Zai Lab Ltd?
Recent forward-looking statements from Zai Lab Ltd include guidance on {"claim":"Capital World Investors will maintain a significant stake in Zai Lab Ltd. for the foreseeable future.","entity and 3 other predictions.